Amplyx Pharmaceuticals is a pharmaceutical company focusing on the development of small molecule drugs, broad-spectrum antifungal agents for the treatment of life-threatening invasive fungal infections due to candida, aspergillus and rare molds. Existing therapies for invasive fungal infections are extremely limited on many fronts—they’re difficult to administer, can have toxic side effects and are ineffective against more potent fungi which have developed resistance. Amplyx is advancing a novel small-molecule therapy, APX001, in clinical development. 

Type
Private
HQ
San Diego, US
Founded
2006
Size (employees)
26 (est)
Website
amplyx.com
Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, US
Report incorrect company information

Key People/Management at Amplyx Pharmaceuticals

Ciara Kennedy

Ciara Kennedy

President and CEO
Mike Hodges

Mike Hodges

Chief Medical Officer
Karen Joy Shaw

Karen Joy Shaw

Chief Scientific Officer
Alan Fuhrman

Alan Fuhrman

CFO
Paul Bien

Paul Bien

Vice President, Program Management & Operations
Susan Dube

Susan Dube

Vice President, Business Development & Administration
Show more

Amplyx Pharmaceuticals Office Locations

Amplyx Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
160 12730 High Bluff Dr
Show all (1)
Report incorrect company information

Amplyx Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2006

Amplyx Pharmaceuticals total Funding

$116.2 m

Amplyx Pharmaceuticals latest funding size

$67 m

Time since last funding

a year ago

Amplyx Pharmaceuticals investors

Amplyx Pharmaceuticals's latest funding round in August 2017 was reported to be $67 m. In total, Amplyx Pharmaceuticals has raised $116.2 m
Show all financial metrics
Report incorrect company information

Amplyx Pharmaceuticals Company Life and Culture

Report incorrect company information